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irectional Coronary
therectomy and Implantation
f Drug-Eluting Stents in
elected Bifurcation Lesions
Logical Combination
aiting Evidence*
ntonio Colombo, MD, FACC
ilan, Italy
laque removal with directional coronary atherectomy (DCA)
nd stent implantation appears to be a very rational binomial
ecause a stent implanted on a lesion with a lower plaque
urden should expand to a larger lumen area (1). A larger
nal lumen has always been a major requirement for most
nterventional coronary procedures. Unfortunately, when
his logic was tested in the AMIGO (Atherectomy before
ulti-link Improves lumen Gain and clinical Outcomes)
rial, a dedicated, randomized trial comparing bare-metal
tenting versus DCA before stenting, the results were quite
iscouraging (2). I always commented on the failure of the
MIGO trial with the statement, “atherectomy does not
ork according to the intention-to-treat principle.” The
esults of DCA in the AMIGO trial were quite suboptimal.
ost of the lesions were left, with more than 60% of plaque
urden, and this fact is, in my opinion, the main reason for
uch a failure.
See page 1941
The advent of drug-eluting stents (DES) giving minimal
ate loss (3,4) made the need to further optimize stent
mplantation, beyond a full apposition and reasonable re-
idual lumen, an unnecessary objective. However, when
ES started to be used in more complex lesions such as
ifurcations, restenosis and the need for new revasculariza-
ion became more frequent (5). The PERFECT (PrE
apamycin-eluting stent FlExi-CuT) registry led by Taka-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the EMO Centro Cuore Columbus, San Raffaele Scientific Institute, Milan,
taly.iko Susuki and published in the current issue of the Journal
6) is a serious attempt to improve this area.
The first item to point out is that this study is a registry
f selected lesions considered suitable for DCA. I like to
tate that this fact is not a real limitation but an appropriate
ay to start: a device or procedure should be used where it
ts the best.
There are several important features about the PERFECT
tudy that need to be highlighted:
Atherectomy should only be used in situations where the
operator expects a good result and low complications. To
satisfy this goal, the interventionist needs to be selective.
There is no question about the selectivity used in the
PERFECT registry: the enrollment of 99 patients in 17
centers in 14 months testifies to this impression.
All patients underwent intravascular ultrasound-guided
DCA. This decision confirms that there was an attempt
to obtain the best possible result aiming for a residual
plaque burden of 60%. This goal was effectively
reached with an average final plaque burden of 55.8% at
the end of DCA. It is interesting that the authors
comment on this result, stating: “debulking was not so
aggressive.” As a comparison, the residual plaque burden
in OARS (Optimal Atherectomy Restenosis Study), one
of the most aggressive investigations with DCA con-
ducted in the U.S., was 58% (7). Only the SOLD
(Stenting After Optimal Lesions Debulking) registry and
ABACAS (Adjunctive Balloon Angioplasty After Cor-
onary Atherectomy Study) achieved better DCA results,
with a final plaque burden of 49% and 45.5%, respectively
(1,8).
The primary end point of the study was binary restenosis.
The decision to adopt this end point is very laudable
because it is the only way to truly evaluate the perfor-
mance of a technique or a device in bifurcation lesions
where restenosis in the side branch may be clinically
silent.
Eighty-one percent of the lesions were located in the left
main or at the ostium of the left anterior descending or of
the circumflex. This decision is a very important selection
criterion to improve effectiveness, safety, and cost benefit
of a more complex and expensive approach.
Atherectomy was performed mainly in the main branch,
with only 3 lesions treated in the side branch as well. This
information confirms that most of the plaques were
confined to the main branch.
No complications occurred during the procedure. This
fact highlights the value of well-trained operators.
In 97 lesions only 1 stent was needed, and in 2 lesions, 2
stents were implanted. To us, this fact highlights the
selection performed by the operators to exclude lesions
with disease extending toward the side branch. It is clear
that plaque removal in the main branch may lower the
risk of plaque shifting from the main branch toward the
side branch. Nevertheless, we cannot understand how a
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November 13, 2007:1946–7 Editorial Commentprocedure performed only on the main branch may
positively affect the lesion of the side branch if such a
lesion is more than a focal ostial narrowing. This con-
sideration is supported by the fact that the average lesion
length in the side branch was 7.1 mm.
The use of an intra-aortic balloon pump was needed only
in 11% of patients. Considering that 82% of the lesions
were located around the left main bifurcation, these data
further testify to the high skills and confidence of the
operators.
ollowing these initial considerations, we now come to the
ain results:
The procedural complications were surprisingly low, with
only a 2% incidence of non–Q-wave myocardial infarc-
tion. These data can be accepted only when taking into
account that short lesions were treated in this registry.
The primary end point, binary restenosis, occurred in 1
lesion on the main branch and in 3 lesions in the side
branch for a total restenosis rate of 4.5% (90% angio-
graphic follow-up). In the 63 patients with lesions
located in the left main trunk, there were no cases of
angiographic restenosis.
At 1 year follow-up, obtained in 97% of patients, there
were no deaths and no myocardial infarctions, and 2
patients required a repeat percutaneous intervention.
Dual antiplatelet therapy was prescribed to all patients
for 1 year. No adverse events occurred in the 63 patients
with lesions located in the left main trunk.
he most important learning and practice points we can
xtract from this study are:
. The excellent results,
. The need to be selective in deciding which lesion can be
treated with such an approach, and
. The need to master the skills of DCA.
he lesion selection is to us the most important area to
laborate. It is important to understand that a “complex
esion” encompasses a variety of categories: one item is a
rue bifurcation with the stenosis in the main branch 10 mm
ong and the one in the side branch 5 mm long, and another
tem is a lesion where the 2 branches have a stenosis of
ength 20 mm or more. Unfortunately, both lesions will be
alled “complex lesions.”
The key elements of the PERFECT registry are the
tatement “suitable morphology for DCA catheter delivery”
nd the information included in Table 3 describing the
uantitative coronary angiographic characteristics of the
esions included. These features define the boundaries
egarding the possibility to generalize these results to the
orld of complex bifurcations.
We are very pleased to see these outstanding outcomes
ecause we know that when a bifurcation lesion satisfies
ractice point 2 and DCA is performed by an operator asescribed in practice point 3, we can achieve such superb
esults. Unfortunately, over this success hover a few uncer-
ainties about the appropriate duration of dual antiplatelet
herapy and the possible interaction between plaque removal
nd late stent malapposition. Only an extended follow-up
nd a larger number of patients may help to answer to these
uestions.
What is missing? We need to know the results we can
xpect when lesions similar to the ones included in the
ERFECT registry are treated with a rapamycin-eluting
tent without prior DCA.
What we should refrain from doing is trying to compare
he results of the PERFECT registry with published data
egarding bifurcation lesions unless we specifically know
ow many of them were suitable for DCA and how many
esions could fit within the standard deviations of the
ngiographic characteristics presented in Table 3 of the
ERFECT registry.
The final logical conclusion is: let us set specific inclusion
nd exclusion criteria and consider a randomized trial.
aybe a pilot study only for left main lesions!
A risk is that the “Master DCA Operators” may become
eluctant to randomize when they are confident about their
urrent strategy (DCA before stenting), and we will be left
ith the skeptical and possibly “imperfect DCA operators”
nrolling patients in the trial.
I sense that we are facing another question without a clear
nswer.
eprint requests and correspondence: Dr. Antonio Colombo, Via
uonarroti 48, 20145 Milan, Italy. E-mail: info@emocolumbus.it.
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